Singh Vijendra, Kim Seongho, Deol Abhinav, Uberti Joseph P, Modi Dipenkumar
Department of Oncology, Karmanos Cancer Institute/Wayne State University, Detroit, MI, USA.
Biostatistics Core, Karmanos Cancer Institute, Department of Oncology, Wayne State University, Detroit, MI, USA.
Leuk Lymphoma. 2022 Apr;63(4):855-864. doi: 10.1080/10428194.2021.1999438. Epub 2021 Dec 5.
T-cell lymphoma (TCL) poses a therapeutic challenge. Allogeneic stem cell transplant (alloSCT) is frequently offered in primary refractory disease or failed autologous transplant. We systematically searched published articles on outcomes of alloSCT in TCL through PubMed and EMBASE database between January 2000 and October 2019. Among 651 identified studies, 22 (888 patients) were included. Forty percent patients had peripheral T-cell lymphoma not otherwise specified, 15% had angioimmunoblastic T-cell lymphoma, 21% had anaplastic large cell lymphoma, 5% had cutaneous T-cell lymphoma, and 19% had other histologic subtypes. Thirty-six percent patients had relapsed/refractory disease. Myeloablative conditioning regimens were used in 55% patients. At two-, three- and five-year post-transplant, overall survival was 57, 54 and 51%, respectively; progression-free survival was 45, 50 and 45%, respectively; non-relapse mortality was 9, 29 and 29%, respectively; relapse rate was 30, 28 and 29%, respectively. Our study shows that alloSCT provides durable remission in T cell lymphoma.
T细胞淋巴瘤（TCL）带来了治疗挑战。异基因干细胞移植（alloSCT）常用于原发性难治性疾病或自体移植失败的情况。我们通过PubMed和EMBASE数据库系统检索了2000年1月至2019年10月间关于TCL中alloSCT结果的已发表文章。在651项已识别的研究中，纳入了22项（888例患者）。40%的患者患有未另行指定的外周T细胞淋巴瘤，15%患有血管免疫母细胞性T细胞淋巴瘤，21%患有间变性大细胞淋巴瘤，5%患有皮肤T细胞淋巴瘤，19%患有其他组织学亚型。36%的患者患有复发/难治性疾病。55%的患者使用了清髓性预处理方案。移植后两年、三年和五年时，总生存率分别为57%、54%和51%；无进展生存率分别为45%、50%和45%；非复发死亡率分别为9%、29%和29%；复发率分别为30%、28%和29%。我们的研究表明，alloSCT能使T细胞淋巴瘤获得持久缓解。
